Guardian Pharmacy (GRDN) EVP awarded 50,000 options at $34.59

Rhea-AI Filing Summary

Guardian Pharmacy Services executive Forbes Kendall received a grant of 50,000 stock options on February 11, 2026. The options have an exercise price of $34.59 per share and relate to Class A common stock. They vest and become fully exercisable on February 11, 2029, and expire on February 11, 2036. Following this grant, Kendall beneficially owns 50,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Forbes Kendall

(Last) (First) (Middle)

300 GALLERIA PARKWAY SE, SUITE 800

(Street)

ATLANTA GA 30339

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardian Pharmacy Services, Inc. [ GRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.59	02/11/2026		A		50,000		(1)	02/11/2036	Class A Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full on February 11, 2029.

Remarks:

Executive Vice President, Sales & Operations

	/s/ Douglas Towns, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardian Pharmacy Services (GRDN) report?

Guardian Pharmacy Services reported a stock option grant to executive Forbes Kendall. The filing shows 50,000 stock options awarded at a $34.59 exercise price, linked to Class A common stock, as part of Kendall’s compensation package.

How many stock options did Forbes Kendall receive from GRDN?

Forbes Kendall received 50,000 stock options from Guardian Pharmacy Services. These options give the right to buy 50,000 shares of Class A common stock at a fixed exercise price of $34.59 per share, once they become exercisable.

When do Forbes Kendall’s GRDN stock options vest and become exercisable?

The 50,000 stock options granted to Forbes Kendall vest and become fully exercisable on February 11, 2029. After that date, Kendall can purchase Class A common stock at the fixed $34.59 exercise price until expiration.

What is the exercise price and expiry date of the GRDN options granted?

The granted stock options have an exercise price of $34.59 per share and expire on February 11, 2036. This gives Forbes Kendall a long exercise window after vesting on February 11, 2029, subject to continued service and plan terms.

Is Forbes Kendall’s ownership in GRDN reported as direct or indirect?

Forbes Kendall’s 50,000 stock options are reported as directly owned. The filing lists the ownership form as direct, with no indication of holding through a trust, partnership, or other indirect entity for this specific derivative position.

What type of transaction code is used in Forbes Kendall’s GRDN Form 4?

The transaction uses code “A,” indicating a grant, award, or other acquisition of derivative securities. This reflects an option grant from Guardian Pharmacy Services rather than an open-market purchase or sale of existing shares.